GE

254.52

+1.23%↑

RTX

144.59

+1.32%↑

CAT

384.99

+0.79%↑

BA

214.58

+5.94%↑

HON

228.81

+1.05%↑

GE

254.52

+1.23%↑

RTX

144.59

+1.32%↑

CAT

384.99

+0.79%↑

BA

214.58

+5.94%↑

HON

228.81

+1.05%↑

GE

254.52

+1.23%↑

RTX

144.59

+1.32%↑

CAT

384.99

+0.79%↑

BA

214.58

+5.94%↑

HON

228.81

+1.05%↑

GE

254.52

+1.23%↑

RTX

144.59

+1.32%↑

CAT

384.99

+0.79%↑

BA

214.58

+5.94%↑

HON

228.81

+1.05%↑

GE

254.52

+1.23%↑

RTX

144.59

+1.32%↑

CAT

384.99

+0.79%↑

BA

214.58

+5.94%↑

HON

228.81

+1.05%↑

Search

Ocugen Inc

Fechado

1.01

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.99

Máximo

1.08

Indicadores-chave

By Trading Economics

Rendimento

-1.5M

-15M

Vendas

717K

1.5M

EPS

-0.05

Margem de lucro

-1,036.462

Funcionários

95

EBITDA

-350K

-14M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+508.65% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

82M

287M

Abertura anterior

1.01

Fecho anterior

1.01

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Ocugen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de jun. de 2025, 20:51 UTC

Ganhos

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de jun. de 2025, 20:48 UTC

Conversa de Mercado

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 de jun. de 2025, 20:46 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 de jun. de 2025, 20:46 UTC

Conversa de Mercado

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 de jun. de 2025, 19:31 UTC

Conversa de Mercado

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 de jun. de 2025, 19:19 UTC

Conversa de Mercado

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 de jun. de 2025, 19:16 UTC

Conversa de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 de jun. de 2025, 18:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de jun. de 2025, 18:42 UTC

Conversa de Mercado

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 de jun. de 2025, 18:39 UTC

Conversa de Mercado
Ganhos

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 de jun. de 2025, 18:29 UTC

Conversa de Mercado

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 de jun. de 2025, 18:18 UTC

Conversa de Mercado

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 de jun. de 2025, 18:16 UTC

Conversa de Mercado

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 de jun. de 2025, 17:16 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 de jun. de 2025, 17:08 UTC

Ganhos

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 de jun. de 2025, 16:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 de jun. de 2025, 16:22 UTC

Ganhos

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

27 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

27 de jun. de 2025, 15:59 UTC

Conversa de Mercado

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 de jun. de 2025, 15:56 UTC

Conversa de Mercado

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparação entre Pares

Variação de preço

Ocugen Inc Previsão

Preço-alvo

By TipRanks

508.65% parte superior

Previsão para 12 meses

Média 6.33 USD  508.65%

Máximo 8 USD

Mínimo 4 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Ocugen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.6818 / 0.74Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

No Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.